Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Tongue Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brenner Tumor 1Breast Neoplasms 1

Interventions

Cetuximab 5Erlotinib Hydrochloride 3Radiotherapy 2Radiation 2Everolimus 2Docetaxel 2Cisplatin 2talactoferrin alfa 1mercaptoundecahydrododecaborate 1VTX-2337 1Taxes 1Sunitinib 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Pharmacogenomic Testing 1Microarray Analysis 1Lenalidomide 1Immunohistochemistry 1Hydroxyurea 1Gene Expression Profiling 1Fluorouracil 1Electrophoresis, Polyacrylamide Gel 1Chemotherapy, Adjuvant 1Carboplatin 1CBLB502 1Biopsy 1Albumin-Bound Paclitaxel 14-boronophenylalanine-fructose 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Tongue Neoplasms × VTX-2337 × Clear all
NCT01334177 2015-03-05

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

University of Washington

Phase 1 Completed
13 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡